Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (115)	4/2/2001 1:28:34 PM
From: tuck	Respond to of 255

No mention of ARDM here, but check the analyst's estimate of market size for inhalable insulin: >>Lilly, Alkermes to extend alliance 'Monster market' beckons in inhalable insulin By Stephanie O'Brien, CBS.MarketWatch.com Last Update: 11:36 AM ET Apr 2, 2001 NEW YORK (CBS.MW) -- Eli Lilly & Co. and Alkermes have agreed to develop inhaled insulin and other products for the treatment of diabetes, the companies announced Monday. Under the terms of their agreement, Alkermes (ALKS: news, msgs, alerts) will get funding for product development, milestone payments and royalties from product sales. The partners, which are already developing an inhaled version of human growth hormone, will develop products that use Alkermes' pulmonary drug delivery system. In exchange, Indianapolis-based Lilly (LLY: news, msgs, alerts) -- the largest U.S. supplier of insulin -- will get exclusive worldwide rights to products resulting from the collaboration. Lilly will be responsible for conducting clinical trials, securing regulatory approvals, and overseeing manufacturing and marketing on a worldwide basis, the companies said. The partners are likely developing both short- and long-acting forms of insulin, said J.P. Morgan analyst Franklin Berger. Leerink Swann & Co. analyst Michael Hearle said Cambridge, Mass.-based Alkermes is likely to receive over $100 million in financial support from Lilly as a result of the deal announced Monday. Alkermes stock rose $1.00 to $22.94 in recent trading, while Lilly shares were down $1.55 to $75.11. "It's a monster market they're going after," Hearle said. However, it's a competitive one, too. Despite Lilly's dominance, Pfizer (PFE: news, msgs, alerts) and Inhaled Therapeutics (INHL: news, msgs, alerts) are developing an inhalable version of insulin that could be on the market in 2003. If those products are approved, sales of inhaled insulin could reach $2 billion in the next several years, Hearle said.<< snip Cheers, Tuck

To: Mark Bong who wrote (115)	4/5/2001 11:16:21 AM
From: tuck	Read Replies (1) \| Respond to of 255

Mark, How about one out of two? >>Aradigm Corporation Receives Milestone Payment From Novo Nordisk for Development of AERx(R) Diabetes Management System HAYWARD, Calif., April 5 /PRNewswire/ -- Aradigm Corporation (Nasdaq: ARDM - news) today announced that the company has received a milestone payment from Novo Nordisk (NYSE: NVO - news) in connection with completing certain clinical and product development milestones for the development of the AERx (R) Diabetes Management System. Aradigm is developing the AERx System with Novo Nordisk to deliver insulin via inhalation for patients with diabetes. ``Novo Nordisk is pleased to be involved with Aradigm in this project, as we believe Aradigm's technology is superior for the pulmonary delivery of insulin,'' said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. ``This is a significant program for our company. We have completed the pre-clinical safety requirements and are preparing for the start of Phase 3 trials.'' Aradigm and Novo Nordisk are in Phase 2 clinical trials with inhaled insulin delivered using the AERx Pulmonary Delivery System. Clinical results to date confirm that pulmonary delivery using the AERx System is a reproducible method for delivering insulin to the bloodstream that is comparable to delivery via subcutaneous administration. ``This is an important accomplishment for Aradigm,'' said Richard Thompson, chairman, president and CEO of Aradigm. ``We are very excited about this program and believe that we have the right non-invasive solution for patients who need insulin. For patients with diabetes, pulmonary delivery of insulin with the AERx System may offer a quick and effective alternative that could dramatically increase their quality of life.'' Aradigm and Novo Nordisk have been collaborating on the development of the AERx Diabetes Management System since 1998. The AERx System uses liquid formulated insulin, which allows for low cost manufacturing, and includes automatic breath control that assures that patients are breathing in the correct manner with each dose of insulin.<< Cheers, Tuck